This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Ilaprazole
- DrugBank Accession Number
- DB11964
- Background
Ilaprazole has been investigated in Helicobacter Infections.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Ilaprazole (DB11964)
- Weight
- Average: 366.44
Monoisotopic: 366.11504701 - Chemical Formula
- C19H18N4O2S
- Synonyms
- Ilaprazole
- Ilaprazolum
- External IDs
- IY 81149
- IY-81149
- IY81149
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Ilaprazole. Amphetamine Ilaprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. Belumosudil The serum concentration of Belumosudil can be decreased when it is combined with Ilaprazole. Budesonide Ilaprazole can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Clodronic acid The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Ilaprazole. Dacomitinib Ilaprazole can cause a decrease in the absorption of Dacomitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Dextroamphetamine Ilaprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. Doxycycline Ilaprazole can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Etidronic acid The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Ilaprazole. Ferrous sulfate anhydrous Ilaprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Noltec
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Sulfinylbenzimidazoles
- Direct Parent
- Sulfinylbenzimidazoles
- Alternative Parents
- Methylpyridines / Alkyl aryl ethers / Substituted pyrroles / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds show 3 more
- Substituents
- Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative / Imidazole / Methylpyridine show 13 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 776Q6XX45J
- CAS number
- 172152-36-2
- InChI Key
- HRRXCXABAPSOCP-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)
- IUPAC Name
- 2-[(4-methoxy-3-methylpyridin-2-yl)methanesulfinyl]-5-(1H-pyrrol-1-yl)-1H-1,3-benzodiazole
- SMILES
- COC1=C(C)C(CS(=O)C2=NC3=C(N2)C=CC(=C3)N2C=CC=C2)=NC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 214351
- PubChem Substance
- 347828288
- ChemSpider
- 185839
- ChEBI
- 135544
- ChEMBL
- CHEMBL2106370
- PharmGKB
- PA165947499
- Wikipedia
- Ilaprazole
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Duodenal Ulcer Due to Helicobacter Pylori 1 4 Completed Treatment Eradication Therapy of Helicobacter Pylori 1 4 Completed Treatment Gastrointestinal Subepithelial Tumors 1 4 Completed Treatment Helicobacter Infections 1 4 Completed Treatment Helicobacter Pylori Eradication Antibiotic 1 4 Completed Treatment Malignant Neoplasm of Stomach 1 4 Completed Treatment Peptic Ulcer 1 4 Unknown Status Treatment Antimicrobial Susceptibility Testing / Triple Therapy 1 3 Completed Treatment Duodenal Ulcer 1 3 Completed Treatment Erosive Esophagitis / Gastro-esophageal Reflux Disease (GERD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, delayed release - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0934 mg/mL ALOGPS logP 2.42 ALOGPS logP 3.04 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 10.1 ChemAxon pKa (Strongest Basic) 4.27 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 72.8 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 111.91 m3·mol-1 ChemAxon Polarizability 40.08 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:06 / Updated at February 21, 2021 18:53